Market Newsdesk

AMSTERDAM, Dec. 17, 2020 /PRNewswire/ — Core Laboratories N.V. (NYSE: “CLB US” and Euronext Amsterdam: “CLB NA”) (“Core,” “Core Lab,” or the “Company”) announced today that it has established an at-the-market equity offering program (the “ATM Program”) under which it may, from time to time, sell its common shares having an aggregate sales price of up to $60,000,000 (the “Shares”), and has entered into an equity distribution agreement (“Equity Distribution Agreement”) with Wells Fargo Securities, LLC (“Wells Fargo Securities”), as sales agent.

Upon delivery of a placement notice and subject to the terms and conditions of the Equity Distribution Agreement, Wells Fargo Securities will use reasonable efforts consistent with its normal trading and sales practices, applicable laws and the rules of the New York Stock Exchange to sell the Shares from time to time based upon Core Lab’s instructions for the sales, including price, time or size limits specified by Core Lab. Pursuant to the Equity Distribution Agreement, sales of the Shares may be made by any method permitted by law, including in ordinary brokers’ transactions, negotiated transactions, block trades, and transactions deemed to be “at-the-market offerings,” as defined in Rule 415 under the Securities Act of 1933, as amended. Wells Fargo Securities’ obligations to sell the Shares under the Equity Distribution Agreement are subject to satisfaction of certain conditions, including customary closing conditions.

Core Lab has agreed to reimburse Wells Fargo Securities for certain specified expenses and has also agreed to provide Wells Fargo Securities with customary indemnification and contribution rights. Core Lab is not obligated to sell any Shares under the Equity Distribution Agreement and may at any time suspend solicitation and offers under the Equity Distribution Agreement. The Equity Distribution Agreement may be terminated by Core Lab at any time by giving written notice to Wells Fargo Securities for any reason or by Wells Fargo Securities at any time by giving written notice to Core Lab for any reason, or immediately under certain circumstances, including, but not limited to, the occurrence of a material adverse change in the Company. The ATM Program pursuant to the Equity Distribution Agreement will automatically terminate upon the issuance and sale of all of the Shares through Wells Fargo Securities.

Core Lab intends to use the net proceeds from the sales of the Shares, if any, for general corporate purposes, which may include, among other things, investments in the development of new products and technology, capital expenditures, repayments of indebtedness, working capital and potential acquisitions. Pending these uses, Core Lab intends to invest the net proceeds in investment-grade interest-bearing obligations, highly liquid cash equivalents, certificates of deposit, or direct or guaranteed obligations of the United States of America.

The Shares will be offered under the Company’s existing shelf registration statement on Form S-3ASR (File No.: 333-245691) filed with the Securities and Exchange Commission (the “SEC”). The offering is being made by means of a prospectus supplement to the prospectus contained in the registration statement. Before making an investment in the Shares, potential investors should read the prospectus and the prospectus supplement for more complete information about Core Lab and the offering. Potential investors may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, the Company or Wells Fargo Securities will arrange, upon request, to send the prospectus. Please direct requests to: Wells Fargo Securities by mail at 500 West 33rd Street, New York, NY 10001, Attention: Equity Syndicate Department, by email to [email protected] or by telephone at (800) 326-5897.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Core Laboratories N.V. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world.

This release, as well as other statements we make, includes forward-looking statements regarding the future revenue, profitability, business strategies and developments of the Company made in reliance upon the safe harbor provisions of Federal securities law. The Company’s outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business conditions, international markets, international political climates, public health crises, such as the COVID-19 pandemic, and any related actions taken by businesses and governments, and other factors as more fully described in the Company’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the SEC. These important factors could cause the Company’s actual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company’s performance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company’s future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.

Visit the Company’s website at www.corelab.com. Connect with Core Lab on Facebook, LinkedIn and YouTube.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/core-lab-announces-60-000-000-at-the-market-equity-offering-program-301195081.html

SOURCE Core Laboratories N.V.

SOUTH EASTON, Mass., Dec. 17, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, and food & beverage industries, today announced a remarkable convergence of global research teams announcing pivotal new insights into COVID-19 biology and disease processes. These data point to potential new pathways to next generation diagnostics and treatments. All teams selected PBI’s Pressure Cycling Technology (“PCT”) platform for their critical sample preparation steps, to help ensure that the greatest abundance and diversity of reproducible results would be revealed in the thousands of proteins involved in the affected biochemical pathways.

The year 2020 will be forever remembered for the outbreak of the COVID-19 pandemic, wreaking a devastating swath of death, damaged lives, and economic destruction globally. Legions of workers in healthcare and essential services have heroically stood up for this challenge.  Thousands of scientists worldwide mobilized into a juggernaut seeking out the unique differences and clues in the SARS-CoV-2 virus and probing for their interaction with the complexities of diverse human responses to infection, to illuminate potent insights into the development of more effective diagnosis, assessment, and treatment. While the first batches of vaccine from several manufacturers are now being shipped, the battle against COVID-19 is far from over. The SARS-CoV-2 virus is a highly variable and rapidly evolving pathogen. It is still not known how long immunity lasts after vaccination. Moreover, as the pandemic continues, initial drugs and vaccines could become less effective against mutated viral strains, as they appear. It is important that scientists continue to monitor and study the virus, to ensure that the arsenal of therapeutics, vaccines, and diagnostics being used to fight this pathogen remain highly effective. 

Dr. Alexander V. Lazarev, Chief Science Officer of PBI, said: “The compelling history of scientists worldwide publishing on PBI’s PCT-based Barocycler system has resulted in its establishment as the method of choice for many teams who recognize that no compromise can be allowed in the critical stage of sample preparation as they work to ensure that the most complete, informative, robust and reproducible data are captured. Recent publications and reports from three independent laboratories located on three different continents highlighted the importance of PBI’s highly effective and reproducible PCT sample preparation platform in studies designed to generate a more thorough understanding of the SARS-CoV-2 biology, etiology, and human response to infection.

Georgetown University (Washington DC, U.S.)

A recent publication from the scientific team at the Clinical and Translational Glycoscience Research Center (glycomics.georgetown.edu) at Georgetown University headed by Associate Professor Miloslav Sanda, Ph.D. highlighted the use of the PCT Barocycler EXT sample preparation system in preparing SARS-CoV-2 glycoprotein samples for analysis. 

Prof. Radoslav Goldman, senior author on the publication, said: “Development of effective antiviral therapies and vaccines requires detailed characterization of the SARS-CoV-2 proteins. The SARS-CoV-2 spike protein controls binding of the virus to human cells; consequently, it is a prime immunization and biotherapeutic target. Our study substantially expands current knowledge of the spike protein’s glycosylation, which has significant influence on viral activation and infectivity. We believe that our data will help in the development of better vaccines and therapies against this devastating disease.”

Westlake University (Hangzhou, China) 

A recent publication from the scientific team at Westlake University headed by Dr. Tiannan Guo, M.D., Ph.D., in collaboration with multiple clinical centers throughout China, discussed findings regarding the impact of COVID-19 infection on protein expression and biochemical processes in the multi-organ injuries experienced by COVID-19 patients.

Dr. Guo, lead study author, commented: “We used multiple Barocycler instruments in preparing 144 tissue samples from seven organs obtained during autopsies of 19 COVID-19 patients. We compared the results to 74 control samples from 56 non-COVID-19 cases. Our team characterized 11,394 proteins, of which over 5,000 proteins were clearly different in COVID-19 patients compared to controls. We believe our study findings offer important new insights on potential therapies.”

Steinbeis Centre (Russelsheim, Germany)

Professor Michael Przybylski, director of the Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry, heads a research project in collaboration with University Clinics in Darmstadt and Klinikum Giessen, Germany targeting the identification of epitopes, the specific regions of pathogen proteins that are recognized by antibodies formed in patients who are infected with SARS-CoV-2.

Professor Przybylski said: “Understanding which antibodies are capable of neutralizing the SARS-CoV-2 virus is crucial for the development of effective vaccines and anti-viral therapeutics.  Characterization of antibody-binding epitopes has historically been performed by indirect methods, e.g., computer-based prediction algorithms. Our team is using a combination of high-pressure treatment in a PCT Barocycler system, followed by selection of strongly bound antibody fragments by a technique called Surface Plasmon Resonance. Finally, identification is then done by mass spectrometry. As a result, we are able to directly identify antibody regions involved in the capture and neutralization of the viral pathogen. We believe this novel method – in which PBI’s PCT Barocycler protein digestion system plays a critical role – will be instrumental in the future development of new, more efficient vaccines and biotherapeutics, as well as more sensitive and specific diagnostic tests for COVID-19 disease.”

Mr. Richard T. Schumacher, President and CEO of PBI, summed up the findings of the three research groups: “We congratulate the scientists at Georgetown, West Lake, and the Steinbeis Centre for their terrific work in elucidating the protein structure of the SARS-CoV-2 virus, especially the critical spike protein; in highlighting disease processes of COVID-19 within multiple organs in infected patients; and for the identification of antibody regions involved in the capture and neutralization of SARS-CoV-2 virus. This information is critical to the design and development of future vaccines, drugs, and diagnostics. The more we know about the SARS-CoV-2 virus, and other potential pathogen threats, the better prepared we will be to prevent future outbreaks/pandemics. Our team is very proud that the PCT platform played an important role in this work. We look forward to bringing the significant capabilities of the PCT platform to many additional academic, government, and industry scientists working on COVID-19 and future biological threats.”

About the Life Sciences Investor Forum

The Life Sciences Investor Forum is a live, interactive investor event held quarterly for public and private companies, investors, and industry professionals from around the world. This day-long, virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. PBI’s President and CEO, Mr. Richard T. Schumacher, is scheduled to present at 11am ET.

DATE:  Thursday, December 17, 2020
TIME:   11am ET
LINK:    https://bit.ly/3mPSVkO

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com 
Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:

Richard T. Schumacher, President & CEO
+1 (508) 230-1828 (T)

Alexander V. Lazarev, Ph.D., Chief Science Officer
+1 (508) 230-1829 (F)

View original content:http://www.prnewswire.com/news-releases/pressure-biosciences-pct-platform-at-forefront-in-generating-pivotal-findings-by-diverse-covid-19-research-teams-in-usa-china-and-europe-301195100.html

SOURCE Pressure BioSciences, Inc.

DENVER, Dec. 17, 2020 /PRNewswire/ — CBD of Denver, Inc. (OTC: CBDD), a full-line CBD and Hemp oil company (“CBDD”) and a producer and distributor of Cannabis and CBD products in Switzerland has signed an agreement with a new US supplier.

The first shipment of 100kg CBD Flower from the Company’s new US partner arrived this week in Switzerland.

Rockflowr Exchange presented products from this new supplier to its regular long-term customers allowing them the first opportunity to secure future delivery and the products were well received.

The Company looks forward to placing a larger order of approximately 400-500kg in mid-January 2021, potentially growing to orders of up to 1,000kg per week.

“As we continue expanding our customer base and our network of suppliers such as this new partnership, we look forward to a robust 2021” stated Pascal Siegenthaler, Rockflowr Managing Director of Sales.

We encourage you to follow us on Instagram: @SwissCBDTrading @Rockflowr @CBDofDenver_Inc @SwissGreenGrow @RockflowrRetail

You may also find the following company pages on LinkedIn: CBDofDenver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG

CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders

CBDD offers a superior CBD product that is full spectrum without depending on THC to activate the benefits of cannabidiols. Black Pearl CBD has 0% THC, but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry. Their website and new product line have been updated and are available at www.blackpearlcbd.com.

Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and you should not place undue reliance on these statements. Any forward-looking statement reflects our current views with respect to future events. We assume no obligation publicly about update or revise these forward-looking statements for any reason.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cbd-of-denver-inc-cbdd-switzerland-signs-contract-with-new-us-supplier-301194621.html

SOURCE CBD of Denver, Inc.

NEW YORK, Dec. 17, 2020 /PRNewswire/ — Genpact (NYSE: G), a global professional services firm focused on delivering digital transformation, and The LIVEKINDLY Collective, a collective of plant-based food and media brands, today announced they are leveraging cloud technology and predictive analytics to reimagine end-to-end operations and drive competitive growth. They are co-innovating to create a digital-first, data-led organization to achieve LIVEKINDLY Collective’s vision to be the preeminent plant-based food company that transforms the global food system at speed.

LIVEKINDLY Collective’s aggressive “farm-to-fork” approach dictates the need for agility. The company is developing everything from seeds that can grow with less water to new cuisine that encourages more consumers to eat plant-based meals. It must reinvent traditional business operations to shift the global food system to a sustainable one. Genpact answers this call by combining modern food production processes with cloud technology that can scale quickly. With fast access to best-in-class equipment and systems, LIVEKINDLY Collective can easily integrate new brands and partners, increasing its speed to market and driving greater impact across its global food value chain. By managing this work in a cloud environment, LIVEKINDLY Collective can combine the benefits of grit and flexibility of an innovative startup with the resources, expertise, and scale of an established enterprise.

Genpact and The LIVEKINDLY Collective will harness the power of predictive analytics and rapid forecasting – analyzing conventional internal information such as product specifications and buying trends, as well as terabytes of relevant external consumer data including social media chatter – to create hyper-personalized customer experiences for buying and consuming plant-based foods. For example, by tracking key influencers and related online dialog in real time, the LIVEKINDLY Collective can quickly determine what to promote when, where, and to whom. In addition, forward-looking intelligence will allow The LIVEKINDLY Collective to better anticipate and match market demand, from managing supply chain operations to knowing what crop to plant when, bringing quality products to market when customers need them most.

“Genpact is a strategic partner helping us build a sustainable future today, while shifting consumer behaviour through more personal engagement, unrivalled customer intimacy, and superior service,” said Kees Kruythoff, chairman and chief executive officer of The LIVEKINDLY Collective. “Genpact’s deep experience in cloud and other digital technologies, combined with its process expertise from managing operations for numerous global consumer goods and retail companies, allows us to operate instinctively and grow faster.”

Built with the enterprise resource planning power of SAP S/4HANA, Genpact’s solution standardizes and connects operations across all core aspects of the business, including customer acquisition, procurement, supply chain management, finance, human resources, and other key functions. By transforming many traditionally siloed, manual processes into an integrated ecosystem of real-time operations that will continue to scale seamlessly as the business grows, The LIVEKINDLY Collective can compete more effectively and make faster, smarter business decisions as consumer demands evolve. Moreover, significantly lower maintenance costs will unlock savings to reinvest in innovation that drives further growth.

Genpact’s expertise in digital technology and consumer goods and retail processes allowed it to create a sophisticated design across all key functional areas in just three weeks, and an end-to-end infrastructure that The LIVEKINDLY Collective launched live in only six months. The Genpact and LIVEKINDLY Collective teams collaborated remotely due to COVID-19 restrictions, and the solution is one of the many SAP S/4HANA installations developed in the cloud during this challenging work environment. The swift time from design to launch allowed The LIVEKINDLY Collective to continue its aggressive growth strategy uninhibited by the pandemic.

“The plant-based food market has seen exponential growth over the last several years, continuing to attract numerous new players, both big and small. Agility and speed-to-market are critical for success, especially for an innovative disruptor like The LIVEKINDLY Collective,” said BK Kalra, global businesses leader, consumer goods and retail at Genpact. “Cloud-based, real-time operations are driving the future of business, and giving The LIVEKINDLY Collective an edge over larger competitors with cumbersome legacy systems. We’re excited to support its growth and vision to promote a sustainable plant-based lifestyle.”  

About The LIVEKINDLY Collective

The LIVEKINDLY Collective was founded on the belief that plant-based alternatives have the power to make the global food system sustainable. Through strategic partnerships with seed growers, producers, and distributors, we are the only company in the plant-based food sector to own and operate the entire value chain. 

As a collective of business leaders and entrepreneurs from across the globe, we are uniquely positioned to create impact with speed, at scale—because of our unique capabilities and purpose-driven mission to effect change through sustainable, cruelty-free plant-based alternatives.

Through our brands Oumph!, The Fry Family Food Co. and LikeMeat, we’re making plant-based eating the new normal and providing our customers with healthy, sustainable, delicious food options. And creating informative, entertaining and inspiring content through our lifestyle media platform, LIVEKINDLY. 

For humanity, our home and those who share it with us. #LIVEKINDLY.

About Genpact

Genpact (NYSE: G) is a global professional services firm that makes business transformation real. We drive digital-led innovation and digitally-enabled intelligent operations for our clients, guided by our experience running thousands of processes primarily for Global Fortune 500 companies. We think with design, dream in digital, and solve problems with data and analytics. Combining our expertise in end-to-end operations and our AI-based platform, Genpact Cora, we focus on the details – all 90,000+ of us. From New York to New Delhi and more than 30 countries in between, we connect every dot, reimagine every process, and reinvent companies’ ways of working. We know that reimagining each step from start to finish creates better business outcomes. Whatever it is, we’ll be there with you – accelerating digital transformation to create bold, lasting results –because transformation happens here. Get to know us at Genpact.com and on LinkedIn, Twitter, YouTube, and Facebook.

MEDIA CONTACTS:

Danielle D’Angelo


Genpact Media Relations – Americas
+1 914-336-7951
[email protected]

Siya Belliappa


Genpact Media Relations – India
+91 9823133365
[email protected]

LIVEKINDLY Media Relations

[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/genpact-and-the-livekindly-collective-leverage-cloud-technology-and-predictive-analytics-to-scale-plant-based-food-production-301195035.html

SOURCE Genpact